{"id":474458,"date":"2020-03-17T14:44:01","date_gmt":"2020-03-17T14:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474458"},"modified":"2020-03-17T14:44:01","modified_gmt":"2020-03-17T14:44:01","slug":"chronic-hepatitis-delta-virus-hdv-infection-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hepatitis-delta-virus-hdv-infection-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_474458.html","title":{"rendered":"Chronic Hepatitis Delta Virus (HDV) Infection Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Chronic<\/a><\/div>\n

DelveInsight has launched a new report on Chronic Hepatitis Delta Virus (HDV) Infection Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic Hepatitis Delta Virus (HDV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan<\/em><\/p>\n

According to the Hepatitis B Foundation, Hepatitis delta, also known as hepatitis D or HDV is a liver infection caused by the hepatitis delta virus that results in the most severe form of viral hepatitis known to humans. However, only those already infected with hepatitis B can acquire hepatitis delta, as it is dependent on the hepatitis B virus to reproduce. The HDV infection is of two types: super infection and co-infection. Super infections occur when a person with chronic hepatitis B becomes infected with hepatitis delta. These types of infections are more common and have a 70\u201290% chance of resulting in a chronic infection of both hepatitis B and delta. Co-infections occur when a person gets infected with hepatitis B and delta at the same time, and have a <5% chance of resulting in chronic infections. HDVC is percutaneously or sexually transmitted through contact with infected blood or blood products. Vertical transmission is possible, but rare.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong>Chronic Hepatitis Delta Virus (HDV) Infection free sample page<\/a><\/p>\n

 <\/p>\n

Chronic Hepatitis Delta Virus (HDV) Infection Epidemiology<\/strong><\/p>\n

The Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> epidemiology division provide insights about historical and current Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken<\/p>\n

 <\/p>\n

Some of the Report Key Facts:-<\/strong><\/p>\n

1. According to the study conducted by Kushner et al., titled “Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes,” the HDV seroprevalence of 3.4% among patients with chronic HBV were tested.<\/p>\n

 2. The study by Patel et al., titled “Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011–2016,”reported a HDV seroprevalence of 42% among HBsAg (HBV surface antigen) carriers.<\/p>\n

 <\/p>\n

Report Key Benefits<\/strong><\/p>\n

1. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> market report covers a descriptive overview and comprehensive insight of the Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> epidemiology Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

2. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> market report provides insights on the current and emerging therapies. <\/p>\n

3. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

4. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong> market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>market.<\/p>\n

 <\/p>\n

“According to study by Patel et al. (2019), the prevalence of anti-HDV among HBV carriers was found to be more in females than in males”<\/strong><\/em><\/p>\n

 <\/p>\n

Some of the key companies working on Chronic Hepatitis Delta Virus (HDV) Infection that are given below:-<\/strong><\/p>\n

1. MYR Pharma Co. <\/p>\n

2. Eiger Bio Pharma Co.<\/p>\n

 <\/p>\n

Name of covered Drugs are given below. <\/strong><\/p>\n

1. <\/strong>Myrcludex B (Bulevirtide)<\/p>\n

2. Lonafarnib with Ritonavir<\/p>\n

 <\/p>\n

Table of Contents<\/a><\/p>\n

1. Key Insights<\/strong><\/p>\n

2. Executive Summary of Chronic Hepatitis Delta Virus (HDV) Infection<\/strong><\/strong><\/p>\n

3. Competitive Intelligence Analysis for Chronic Hepatitis Delta Virus (HDV) Infection<\/strong><\/strong><\/p>\n

4. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong>: Market Overview at a Glance<\/strong><\/p>\n

5. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong>: Disease Background and Overview<\/strong><\/p>\n

6. Patient Journey<\/strong><\/p>\n

7. Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>Epidemiology and Patient Population<\/strong><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n

9. Unmet Needs<\/strong><\/p>\n

10. Key Endpoints of Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>Treatment<\/strong><\/p>\n

11. Marketed Products<\/strong><\/p>\n

12. Emerging Therapies<\/strong><\/p>\n

13. Chronic Hepatitis Delta Virus (HDV) Infection<\/strong>: Seven Major Market Analysis<\/strong><\/p>\n

14. Attribute analysis<\/strong><\/p>\n

15. 7MM: Market Outlook<\/strong><\/p>\n

16. Access and Reimbursement Overview of Chronic Hepatitis Delta Virus (HDV) Infection<\/strong><\/strong><\/p>\n

17. KOL Views<\/strong><\/p>\n

18. Market Drivers<\/strong><\/p>\n

19. Market Barriers<\/strong><\/p>\n

20. Appendix<\/strong><\/p>\n

20.1. Bibliography<\/strong><\/p>\n

20.2. Report Methodology<\/strong><\/p>\n

21. DelveInsight Capabilities<\/strong><\/p>\n

22. Disclaimer<\/strong><\/p>\n

23. About <\/strong>DelveInsight<\/a><\/p>\n

 <\/p>\n

Why should you buy this Chronic Hepatitis Delta Virus (HDV) Infection <\/strong><\/strong>market report? <\/strong><\/p>\n